We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current NWBO market cap is 392.49M. The company's latest EPS is USD -0.0593 and P/E is -2.87.
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 1.29M | 1.01M | 1.68M | 1.93M | 1.38M |
| Operating Income | -86.61M | -52.7M | -67.18M | -55.51M | -66.51M |
| Net Income | -529.82M | 179.13M | -105.03M | -64.37M | -85.19M |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 32.9M | 40.16M | 31.32M | 27.87M | 26.73M |
| Total Liabilities | 395.85M | 164.15M | 136.37M | 74.92M | 105.71M |
| Total Equity | -362.95M | -123.99M | -128.1M | -65.77M | -94.49M |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -32.09M | -38.3M | -52.78M | -53.64M | -57.02M |
| Investing | -8.14M | -6.02M | -2.9M | -3.44M | -1.01M |
| Financing | 52.7M | 48.13M | 41.97M | 52.76M | 56.79M |
| Market Cap | 392.49M |
| Price to Earnings Ratio | -2.87 |
| Price to Sales Ratio | 170 |
| Price to Cash Ratio | 113.33 |
| Price to Book Ratio | -3.09 |
| Dividend Yield | - |
| Shares Outstanding | 1.44B |
| Average Volume (1 week) | 2.65M |
| Average Volume (1 Month) | 2.26M |
| 52 Week Change | -37.95% |
| 52 Week High | 0.4977 |
| 52 Week Low | 0.16845 |
| Spread (Intraday) | 0 (0.73%) |
| Company Name | Northwest Biotherapeutics Inc (QB) |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https:// |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
